tumor necrosis factor-related apoptosis-inducing ligand / Bcl-2 Cancer Research Results

TRAIL/rTRAIL, tumor necrosis factor-related apoptosis-inducing ligand: Click to Expand ⟱
Features:

Recombinant TRAIL - Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Recommended Abbreviation: rTRAIL

Alternative Names: Recombinant TRAIL, recombinant TNFSF10, Apo2L/TRAIL

Type: Recombinant protein / biologic anticancer agent / death-receptor agonist

Function: Recombinant TRAIL binds primarily to the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B), causing death-inducing signaling complex formation, caspase-8 activation, downstream caspase activation, and apoptosis. Many cancer cells are more sensitive to TRAIL-induced apoptosis than normal cells, although resistance is common.

Cancer: ↑ TRAIL-induced death-receptor signaling is generally favorable because it promotes extrinsic apoptosis in susceptible cancer cells. Recombinant TRAIL and TRAIL-receptor agonists have shown substantial preclinical anticancer activity, although clinical efficacy has been limited by short circulating half-life, receptor biology, and intrinsic or acquired TRAIL resistance.
Bcl-2, B-cell CLL/lymphoma 2: Click to Expand ⟱
Source: HalifaxProj (inhibit) CGL-Driver Genes
Type: Antiapoptotic Oncogene
The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID.
Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells.
Scientific Papers found: Click to Expand⟱
8152- lamb,  TRAIL/rTRAIL,    Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4
- in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
TumCD↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, cFLIP↓, XIAP↓, BID↑, DR4↑, p‑NF-kB↓, p‑IκB↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Bcl-2↓, 1,   BID↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   cFLIP↓, 1,   DR4↑, 1,   TumCD↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

p‑IκB↓, 1,   p‑NF-kB↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Bcl-2, B-cell CLL/lymphoma 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:474  Target#:27  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page